Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS: DUSA)

Dernières nouvelles pour Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS:DUSA)

Davis Fundamental ETF Trust Davis Select U.S. Equity ETF

Davis Select U.S. Equity ETF

Financial Services

Healthcare

Consumer Cyclical

Technology

Communication Services

Energy

Consumer Defensive

Industrials

Basic Materials

Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities issued by U.S. companies. The funds portfolio generally contains between 15 and 35 companies. It may invest a portion of its assets in financial services companies. The fund may also invest in mid- and small-capitalization companies, which the manager considers to be those companies with less than $10 billion in market capitalization. It may invest up to 20% of net assets in non-U.S. companies. The fund is non-diversified.

Meta Platforms, Inc.

Berkshire Hathaway Inc., Class B

Capital One Financial Corp.

Amazon.Com Inc

Humana Inc.

Markel Corp.

Viatris Inc.

Alphabet Inc.  Class 'C'

Us Bancorp

Wells Fargo & Co.

Cvs Health Corp.

Mgm Resorts International

Applied Materials, Inc.

Davis Select US Equity ETF

Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) is facing a lawsuit filed by the Consumer Financial Protection Bureau (CFPB), which accuses the bank of cheating millions of consumers out of <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/01/42871340/regional-banks-can-thrive-despite-big-bank-dominance-truist-securities-highlights-three-key-paths-for-thriving-regional-banks" rel="noreferrer noopener">more than $2 billion in lost interest.</a>
In a <a target="_blank" href="https://www.consumerfinance.gov/about-us/newsroom/cfpb-sues-capital-one-for-cheating-consumers-out-of-more-than-2-billion-in-interest-payments-on-savings-accounts/" rel="noreferrer noopener">statement</a>, the CFPB claims that Capital One falsely advertised its &#8220;360 Savings&#8221; account as offering one of the best interest rates in the nation, only to freeze the rate at a low level while rates increased across the country.
Between late 2019 and mid-2024, Capital One kept the interest rate on its 360 Savings account at just 0.30%, even as market rates soared. Simultaneously, Capital One introduced the &#8220;360 Performance Savings&#8221; account, which paid a substantially higher rate—at one point, more than 14 times the rate of 360 Savings.
Despite this, Capital One allegedly failed to notify existing 360 Savings accountholders about the new account and worked to obscure its existence.
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/market-summary/25/01/42867184/yield-curve-normalization-cheap-valuation-eps-growth-to-boost-banks-in-2025-truist-initiates-coverage-on-these-14-regional-names" rel="noreferrer noopener">Yield Curve Normalization, Cheap Valuation, EPS Growth To Boost Banks In 2025: Truist Initiates Coverage On These 14 Regional Names</a>
The CFPB alleges Capital One deliberately misled customers by hiding the more lucrative 360 Performance Savings account. The bank named and marketed the two accounts similarly, eliminated mentions of 360 Savings on its website, and did not inform existing customers about the new product.
The bank even prohibited employees from informing 360 Savings accountholders about the higher-paying account, thus keeping them locked into the lower-yielding product.
Per CFBP, Capital One marketed its 360 Savings as a &#8220;high-interest&#8221; account with one of the nation&#8217;s best rates, only to mislead customers by freezing the rate at 0.30%. At the same time, it marketed the 360 Performance Savings account at much higher rates, ranging from 0.40% in April 2022 to 4.35% in January 2024.
The CFPB claims that Capital One&#8217;s actions amounted to a violation of the Truth in Savings Act by misrepresenting the interest rates for 360 Savings and unfairly keeping customers in the dark about the more beneficial 360 Performance Savings account.
The lawsuit seeks to halt the alleged unlawful conduct, provide restitution to affected customers, and impose civil penalties on the bank.
CFPB Director Rohit Chopra criticized Capital One for &#8220;baiting people with promises they can&#8217;t live up to,&#8221; and emphasized the harm caused by these deceptive practices.
&#8220;The CFPB&#8217;s lawsuit seeks to stop the companies&#8217; unlawful conduct, provide redress for harmed consumers, and impose civil money penalties, which would be paid into the CFPB&#8217;s victims relief fund,&#8221; stated Chopra.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, COF stock has gained over 43% in the past year.
Investors can gain exposure to the stock via&nbsp;Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DUSA#BATS">DUSA</a>)
Price Action: COF shares are trading higher by 1.12% to $182.35 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42836744/baby-its-cold-outside-these-5-winter-ready-stocks-have-what-it-takes-to-make-you-feel-warm-and-cozy" target="_blank" rel="noreferrer noopener">Baby, It&#8217;s Cold Outside: These 5 Winter-Ready Stocks Have What It Takes To Make You Feel Warm And Cozy</a></li>
</ul>
Image via Shutterstock.

Equities

Government

News

Markets

Movers

General

DUSA

CFPB Sues Capital One Over Alleged $2 Billion In Lost Interest For Consumers

Google parent Alphabet (NASDAQ: GOOG GOOGL) joined rivals Apple (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) and Microsoft (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) in the prestigious <a href="https://www.benzinga.com/news/20/01/15144632/stocks-that-hit-52-week-highs-on-friday">$1 trillion</a> market value club on Friday, aka &ldquo;The Four Comma Club.&rdquo;
This is the first time the internet search giant has joined the $1 trillion pantheon and that&#39;s good news not only for investors in the stock, but for those holding some of the nearly 170 exchange traded funds that own the stock.
&ldquo;Alphabet&rsquo;s shares are among a small group of stocks found in the top holdings of both mutual funds and hedge funds, two types of institutions whose investing styles tend to be markedly different, a Goldman Sachs analysis showed,&rdquo; <a href="https://www.reuters.com/article/us-usa-funds-google/which-company-just-hit-1-trillion-google-it-idUSKBN1ZF2SH">reports Reuters.</a>
Some well-known ETFs are also big Alphabet holders. Let&#39;s have a look at a few here.
<h3>Fidelity MSCI Communication Services Index ETF (FCOM)</h3>
By less than 20 basis points over the ETF with the second-largest Alphabet stake, the Fidelity MSCI Communication Services Index ETF (NYSEARCA: FCOM) leads the way with an 11.77% weight to the stock. That percentage jumps to around 23% when accounting for both the &ldquo;A&rdquo; and &ldquo;C&rdquo; share classes, something that FCOM and rival cap-weighted communication services ETFs do with Alphabet stock.
&nbsp;
Another perk of FCOM is that with its annual fee of 0.084% per year, or $8.40 on a $10,000 stake, it&#39;s the cheapest ETF tracking this sector. 5G deployment is another reason to consider FCOM this year.
&nbsp;
&ldquo;Many of the bellwether companies in the communication services sector gave power to 4G, and others showed us truly world-changing use cases for mobile broadband. I believe the same will be true of 5G,&rdquo; <a href="https://www.fidelity.com/learning-center/trading-investing/markets-sectors/2020-outlook-communications">said Fidelity in a recent note</a>. &ldquo;From a consumer standpoint, 5G will be dramatically faster but less of an improvement over the last generational shift, which introduced mobile broadband to the world. So, what is revolutionary about 5G? The answer lies with the proliferation of connected devices, appliances, systems, and more&mdash;also known as the internet of things&mdash;and where that collected data can take us.&rdquo;
<h3>Davis Select U.S. Equity ETF (DUSA)</h3>
The Davis Select U.S. Equity ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dusa#NASDAQ">DUSA</a>) is a focused, actively managed ETF that can be used as an alternative or a complement to broader, passive domestic equity strategies. Just three ETFs, including the aforementioned FCOM, have larger Alphabet weights than the 10.72% DUSA devotes to the stock.
&nbsp;
&ldquo;Davis Advisors&rsquo; management style largely targets durable businesses with above average margin returns, strong competitive advantages and durability. Companies also have to show strong management that have been in place for over five years as long-term investors can be sure that these are ethical, honest people that will help the business last,&rdquo; <a href="https://www.etftrends.com/davis-advisors-actively-managed-etfs-are-backed-by-years-of-expertise/">according to ETF Trends</a>.
DUSA&#39;s overweight exposure to Alphabet is helping the fund slightly outpace the S&amp;P 500 to start 2020.
<h3>Invesco NASDAQ Internet ETF (PNQI)</h3>
Alphabet&#39;s business lines are sprawling, but the company remains widely viewed as an internet firm. To that end, Invesco NASDAQ Internet ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pnqi#NASDAQ">PNQI</a>) is the internet ETF with largest allocation to the company at about 8.20%, making the stock the fund&#39;s second-largest holding.
The $557.3 million PNQI, which turns 12 years old in June, follows the NASDAQ Internet Index. That index &ldquo;is designed to track the performance of the largest and most liquid US-listed companies engaged in internet-related businesses and that are listed on one of the major US stock exchanges,&rdquo; <a href="https://www.invesco.com/us/financial-products/etfs/product-detail?productId=ETF-PNQI">according to Invesco</a>.
Just six ETFs, including FCOM and DUSA, have larger Alphabet exposure than PNQI.
<h3 class="western">TigerShares China-U.S. Internet Titans ETF (TTTN)</h3>
Perhaps a hidden gem in the world of internet ETFs, the TigerShares China-U.S. Internet Titans ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tttn#NASDAQ">TTTN</a>) combines U.S. and Chinese internet equities, giving it a unique methodology in this category.
The fund tracks the Nasdaq China US Internet Tiger Index, which is usually home to the 10 largest American and 10 biggest Chinese internet companies that are publicly traded.
Hence, an almost 8% weight to Alphabet is found in this ETF.
Related Links
<a href="https://www.benzinga.com/trading-ideas/long-ideas/20/01/15132129/3-etfs-to-watch-in-a-post-phase-one-trade-world">3 Trade Deal ETFs Ready to Rally</a>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/20/01/15124177/doubling-down-on-sustainability-blackrock-ishares-planning-major-esg-etf-expansion">This Leveraged FANG ETN Is Luring Traders</a>

Long Ideas

Sector ETFs

Tech

Trading Ideas

ETFs

AAPL

FCOM

GOOG

GOOGL

MSFT

PNQI

TTTN

4 ETFs For Alphabet's Ascent Into The Four Comma Club

Actively managed exchange traded funds still represent just a sliver of overall ETF assets in the U.S., but several of this year&#39;s most successful new ETFs are active funds.
That group includes the Davis Select U.S. Equity ETF (NASDAQ: <a class="ticker" href="/stock/dusa#NASDAQ">DUSA</a>), which debuted in January courtesy of New York-based Davis Investment Advisors. The money management firm is over 45 years old and had $25 billion in assets under management at the end of last year.
DUSA is managed by Chris Davis and his partner Danton Goei. With over $32 million in assets under management, easily enough to call it a success among 2017&#39;s rookie ETFs, DUSA is concentrated ETF with just 21 holdings.
The firm&#39;s other ETFs include the Davis Select Financial ETF (NASDAQ: <a class="ticker" href="/stock/dfnl#NASDAQ">DFNL</a>) and the Davis Select Worldwide ETF (NASDAQ: <a class="ticker" href="/stock/dwld#NASDAQ">DWLD</a>).
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/17/04/9290513/jpmorgan-adds-a-bond-etf-to-its-asset-management-unit">JPMorgan Adds A Bond ETF To Its Asset Management Unit</a>
&ldquo;Since Davis is by nature an actively managed shop, it is safe to say that all three of these ETFs join the growing list of actively managed strategies in the marketplace as well, and also demonstrates to us yet another well-known mutual fund/SMA manager entering the ETF party,&rdquo; <a href="http://streetonefinancial.com/">Street One Financial</a> Vice President Paul Weisbruch said in a note out Tuesday.
DUSA allocates 52.7 percent of its combined weight to financial services and industrial stocks. By comparison, the S&amp;P 500 devotes just over 24 percent combined to those two sectors. Consumer discretionary and energy stocks combine for 26.1 percent of DUSA&#39;s weight. The ETF can hold between 15 and 35 components.
&ldquo;Davis Advisors conducts extensive research to try to identify businesses that possess characteristics that they believe foster the creation of long-term value, like proven management, durable franchise and business model, and sustainable competitive advantages, along with targeting in those that are trading at discounts to their intrinsic value,&rdquo; <a href="https://www.etftrends.com/2017/02/all-star-manager-davis-discusses-top-ideas-new-etf-strategy/">according to ETF Trends</a>.
The Davis team emphasizes other fundamental factors, including cash flow and debt, when selecting DUSA&#39;s member firms.
Top 10 holdings in the new ETF include Berkshire Hathaway Inc. (NYSE: <a class="ticker" href="/stock/brk-b#NYSE">BRK-B</a>), Amazon.com Inc. (NASDAQ: <a class="ticker" href="/stock/amzn#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ: <a class="ticker" href="/stock/goog#NASDAQ">GOOG</a>). Those stocks combine for a quarter of the new ETF&#39;s weight.
DUSA charges 0.6 per year, or $60 on a $10,000 investment.

Broad U.S. Equity ETFs

New ETFs

AMZN

BRK-B

DFNL

DWLD

A Solid Start For A New Active ETF

C.K. Cooper &amp; Company reiterates DUSA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/dusa#NASDAQ">DUSA</a>) with a Buy and maintains $9.50 PT.

Reiteration

Analyst Ratings

C.K. Cooper & Company Reiterates Buy on DUSA Pharmaceuticals, Inc., Maintains $9.50 PT

Caraco
Pharmaceutical Laboratories, Ltd. ("CPL"), a wholly owned subsidiary of Sun
Pharmaceutical Industries Limited ("Sun Pharma"), and DUSA Pharmaceuticals,
Inc. (Nasdaq: <a class="ticker" href="/stock/dusa#Nasdaq">DUSA</a>) ("DUSA") today announced that they have received notice
from the Federal Trade Commission granting early termination of the waiting
period for U.S. antitrust review under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended ("HSR Act"), in connection with the
previously announced acquisition of the outstanding shares of DUSA by Caraco
Acquisition Corporation ("Purchaser"), a wholly owned subsidiary of CPL.
Accordingly, the condition to the closing of the tender offer with respect to
the expiration or termination of the applicable waiting period under the HSR
Act has been satisfied. The transaction remains subject to other closing
conditions as set forth in the offer to purchase filed by Purchaser and
certain of its affiliates with the U.S. Securities and Exchange Commission
("SEC") on November 21, 2012.

The tender offer to acquire all of the outstanding shares of common stock of
DUSA for $8.00 per share, net to the seller in cash without interest and less
any required withholding taxes, was commenced on November 21, 2012. The tender
offer is being made pursuant to the offer to purchase and related letter of
transmittal, each dated November 21, 2012. The tender offer is scheduled to
expire at midnight, New York time, on December 19, 2012 (at the end of the
day), unless extended or earlier terminated in accordance with the offer to
purchase and the applicable rules and regulations of the SEC.

Caraco, DUSA Pharma Announce Early Termination of Hart-Scott-Rodino Waiting Period for Tender Offer

Shares of DUSA Pharma Up 38+% Following $8/Share Bid from Sun Pharma

DUSA Pharmaceuticals,
Inc.^® (Nasdaq: <a class="ticker" href="/stock/dusa#Nasdaq">DUSA</a>), a dermatology company that is developing and marketing
its Levulan^® (aminolevulinic acid HCl) Photodynamic Therapy (PDT) platform,
today announced results of an investigational study designed to examine and
compare the safety and efficacy of broad area application of the
Levulan^® Kerastick^® with or without occlusive dressing (where the treatment
area is covered or wrapped) in conjunction with the BLU-U^® for the treatment
of minimally to moderately thick actinic keratoses (AKs) on the upper
extremities. The study showed a statistically significant lesion reduction and
complete clearance of actinic keratoses of the extremities (hands and arms)
when compared to treatment with vehicle.  The use of occlusion resulted in a
statistically significant improvement in lesion clearance rates compared to
treatment without occlusion. The study utilized the Levulan^® Kerastick^®
(aminolevulinic acid HCl) for Topical Solution, 20% with the BLU-U^® Blue
Light Photodynamic Therapy Illuminator which is FDA approved for the treatment
of minimally to moderately thick actinic keratoses (AKs) of the face or
scalp.

DUSA Pharma Says Positive Results in Phase 2 Actinic

Dusa Pharmaceuticals (NASD: DUSA) reports second-quarter EPS of $0.06 versus the estimated $0.06 per share, in-line. Revenues came in at $11.7M versus the estimated $11.85M, missing by -1.3%.

Earnings

Dusa Pharmaceuticals Reports Q2 EPS $0.06 vs $0.06 Est; Revenues $11.7M vs $11.85M Est

Dusa Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/dusa#NASDAQ">DUSA</a>) reports first-quarter EPS of $0.08 versus the estimated $0.07 per share, beating by +14.3%. Revenues came in at $13.4M versus the estimated $12.92M, beating by +3.7%.

Guidance

Dusa Pharmaceuticals Reports Q1 EPS $0.08 vs $0.07 Est; Revenues $13.4M vs $12.92M Est

DUSA Pharmaceuticals, Inc.® (Nasdaq: <a class="ticker" href="/stock/dusa#Nasdaq">DUSA</a>), a dermatology company that is developing and marketing its Levulan® Photodynamic Therapy (PDT) platform, announced today that patient enrollment is complete in its Phase 2 clinical trial studying the broad area application with 1, 2 and 3-hour (short) drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp. DUSA also completed enrollment in its pilot Phase 2 clinical trial studying the safety and efficacy of treating AKs on the upper extremities. 

Both studies are utilizing the Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% with the BLU-U® Blue Light Photodynamic Therapy Illuminator. The FDA-approved labeling for Levulan® Kerastick® requires application of Levulan® to individual AK lesions, but in these clinical trials a broad area application method is being utilized, where Levulan® is applied to an entire skin region.

DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan Kerastick Photodynamic Therapy  

According to a research report published earlier today, C.K. Cooper has initiated coverage on DUSA Pharmaceuticals Inc.(NASDAQ: <a class="ticker" href="/stock/dusa#NASDAQ">DUSA</a>) with a Buy rating and $8 PT.

In the report, C.K. Cooper commented, “We expect a blow-out fourth quarter benefiting from strong seasonal demand combined with stocking orders resulting from the announced price increase during the fourth quarter, which took effect Jan. 1, 2012. This should contribute to a very strong finish to what we expect to be the second full year of profitability of Dusa.”

Dusa Pharmaceuticals closed yesterday at $4.65.

Price Target

Initiation

UPDATE: C.K. Cooper Initiates Coverage on DUSA Pharmaceuticals

CK Cooper Initiates Coverage on Dusa Pharmaceuticals at Buy, Announces PT of $8

<div> 
Referencing the <a title="Weekly Traders Homework: Frustrated Bears (w/Economic Calendar &amp; Stock Radar)" href="http://michaelkudrna.com/2012/01/weekly-traders-homework-frustrated-bears-weconomic-calendar-stock-radar/" target="_blank">weekly homework and stock radar</a>, I am highlighting a few of the <a href="http://michaelkudrna.com/tag/charts/" class="st_tag internal_tag" rel="tag" title="Posts tagged with Charts">charts</a> below for <a href="http://michaelkudrna.com/tag/potential-trades/" class="st_tag internal_tag" rel="tag" title="Posts tagged with Potential Trades">potential trades</a> in undervalued stocks.
We finally saw signs of consolidation this morning, but it was short-lived creating continued frustration for the bears.  The trend over the past few months has been that gap-ups tend to drift down towards the rest of the day and gap-downs tend to drift up the rest of the day.  Today continued that trend as we drifted back towards even on the day.
I expect this type of action may continue for the week as market players re-position their portfolios after the <a href="http://michaelkudrna.com/tag/fomc/" class="st_tag internal_tag" rel="tag" title="Posts tagged with FOMC">FOMC</a> decision/data last week.  Bonds rose significantly and as I noted <a title="Weekly Traders Homework: Frustrated Bears (w/Economic Calendar &amp; Stock Radar)" href="http://michaelkudrna.com/2012/01/weekly-traders-homework-frustrated-bears-weconomic-calendar-stock-radar/" target="_blank">Sunday night</a>, we are seeing a time that a large disconnect between bonds and equities can grow.  The day these two correlate once again may be a very devastating day as the disconnect grows larger.  You can expect it to be more of a whipsaw than a slow drift back towards being correlated, creating a great deal of pain for those not prepared.  This will mean we need to stay disciplined and not overextend ourselves without ample cash reserves and proper exit strategies/stop losses.  I don't expect to see this type of whipsaw for many weeks though, maybe even a few months away still.
Look for this type of consolidation action to continue for the week with more clarity after jobs data is released on Friday.  This will be a very important jobs report that will determine if jobs are truly starting a new growing trend or if last month's data was a one-off report that we can't get behind.  The other curve-ball to look out for is Europe/<a href="http://michaelkudrna.com/tag/greece/" class="st_tag internal_tag" rel="tag" title="Posts tagged with Greece">Greece</a>.  Many months ago, we were hopeful we'd stop focusing on every European headline in the markets and we finally received that disconnect in December.  With Greek default chatter still continuing and concerning some, the point to remember is we are more prepared for this outcome than before.  While negative news could provide some weakness, we should have plenty of support from dip-buyers anxious to join in.  It is the unexpected news which we do not see coming that is most devastating.  A Greek default is seemingly not that type of negative news.
I'm still focusing on charts that are showing overall strength with established trend-line support levels for favorable risk-reward buys. In a truly healthy market, I am more than willing to buy on breakouts expecting momentum traders to follow. In this market, I am finding that many breakouts are fizzling fast due to overall fearful sentiment and fast profit-takers. With that being said, I am more inclined to make moves near trend line support rather than breakouts.
[Related: <a onclick="javascript:pageTracker._trackPageview('/outgoing/feedburner.google.com/fb/a/mailverify?uri=MichaelKudrna&amp;loc=en_US');" href="http://feedburner.google.com/fb/a/mailverify?uri=MichaelKudrna&amp;loc=en_US" target="_blank">CLICK HERE TO REGISTER FOR A DAILY EMAIL NEWSLETTER OF OUR ARTICLES</a>]
—
<a href="http://michaelkudrna.com/tag/iridium-communications-irdm/" class="st_tag internal_tag" rel="tag" title="Posts tagged with Iridium Communications (<a class="ticker" href="/stock/irdm#">IRDM</a>)">Iridium Communications (<a class="ticker" href="/stock/irdm#">IRDM</a>)
Yahoo Finance Profile:
<blockquote>Iridium Communications Inc. provides mobile voice and data communications services through satellites to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers worldwide. It offers post-paid mobile voice and data satellite communications services; prepaid mobile voice satellite communications services; high-speed data services; machine-to-machine services for sending and receiving data from one location to other; and ancillary services, including inbound connections from the public switched telephone networks, SMS, SIM, activation, customer reactivation, and other peripheral services to commercial customers. The company also offers traditional voice, netted voice, data, messaging, and paging services, as well as maintenance services for the DoD's dedicated gateway; and offers voice and data solutions, including personnel tracking devices; over-the-horizon aircraft communications applications; submarine communications applications; specialized communications solutions for high-value individuals; asset tracking devices for equipment, vehicles, and aircraft; and secure mobile communications and data devices for the military and intelligence community, such as secure satellite handsets to U.S. government customers. In addition, it manufactures and sells satellite handsets, voice and data modems, high-speed data devices, and machine-to-machine data devices. Further, the company offers accessories for its devices, including holsters, earbuds, portable auxiliary antennas, antenna adaptors, USB data cables, and charging units. Additionally, it provides engineering and support services to commercial and government customers. The company sells products and services to commercial end-users through service providers, value-added resellers, and value-added manufacturers. As of March 31, 2011, it had approximately 447,000 billable subscribers. The company was founded in 2000 and is headquartered in McLean, Virginia.
</blockquote>
Notes On Yahoo Finance <a href="http://michaelkudrna.com/tag/fundamentals/" class="st_tag internal_tag" rel="tag" title="Posts tagged with Fundamentals">Fundamentals</a>:
IRDM has a modest forward P/E of only 12 with an PEG Ratio of only .81. As of January 13, IRDM has a significant short ratio of over 25 which is about 19% of the float short.  This means IRDM is a strong candidate for a short squeeze on further price appreciation.  With $125 million in cash and $325 million in debt, it is a concern for some.  However, looking at the balance sheet, most of the debt is considered long-term rather than short-term liabilities.  It should also be noted that the Book-Value-Per-Share is $9.45, well above the current stock price.  Lastly, the median price target for three analysts is $12 meaning we have plenty of room to rise to meet these analysts targets.
Annotated Chart and Trade Details:
<a onclick="javascript:pageTracker._trackPageview('/downloads/wp-content/uploads/2012/01/IRDM-1-30.png');" href="http://michaelkudrna.com/wp-content/uploads/2012/01/IRDM-1-30.png"><img class="aligncenter size-medium wp-image-4525" title="IRDM 1-30" src="http://michaelkudrna.com/wp-content/uploads/2012/01/IRDM-1-30-300x166.png" alt="" width="300" height="166" /></a>
<a href="http://michaelkudrna.com/tag/dusa-pharma-dusa/" class="st_tag internal_tag" rel="tag" title="Posts tagged with DUSA Pharma (<a class="ticker" href="/stock/dusa#">DUSA</a>)">DUSA Pharma (<a class="ticker" href="/stock/dusa#">DUSA</a>)
Yahoo Finance Profile:
<blockquote>DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (<a class="ticker" href="/stock/pdt#">PDT</a>) and other products for common skin conditions primarily in the United States, Canada, and Korea. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The company also markets the BLU-U without Levulan for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions; and non-PDT drug products, such as ClindaReach and AVAR products. DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts.
</blockquote>
Notes On Yahoo Finance Fundamentals:
DUSA has a forward P/E of only 12 with ample cash-to-debt of $24 million in cash to no debt. As of January 13, DUSA has a short ratio of over 10 which is over 4% of the float short.  A 10-day cover is significant, but as volume increases, that will reduce very fast.  One analyst has a price target of $6.50, which is 43% higher from the current stock price.
Annotated Chart and Trade Details:
<a onclick="javascript:pageTracker._trackPageview('/downloads/wp-content/uploads/2012/01/DUSA-1-30.png');" href="http://michaelkudrna.com/wp-content/uploads/2012/01/DUSA-1-30.png"><img class="aligncenter size-medium wp-image-4526" title="DUSA 1-30" src="http://michaelkudrna.com/wp-content/uploads/2012/01/DUSA-1-30-300x165.png" alt="" width="300" height="165" /></a>
<a href="http://michaelkudrna.com/tag/the-medicines-company-mdco/" class="st_tag internal_tag" rel="tag" title="Posts tagged with The Medicines Company (<a class="ticker" href="/stock/mdco#">MDCO</a>)">The Medicines Company (<a class="ticker" href="/stock/mdco#">MDCO</a>)
Yahoo Finance Profile:
<blockquote>The Medicines Company, a global pharmaceutical company, provides various medicines to hospitals for advancing the treatment of critical care patients primarily in the United States and Europe. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; and Cleviprex, an intravenous small molecule calcium channel blocker for the reduction of blood pressure. The company's developing products comprise Cangrelor, which is in Phase 3 clinical trial acts as an intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation; Oritavancin that is in Phase 3 clinical trial for the treatment of serious gram-positive bacterial infections, including acute bacterial skin and skin structure infections; and MDCO-2010, a small molecule serine inhibitor, is in Phase 2 clinical trial for the reduction of blood loss during surgery. It also provides MDCO-216 that is in Phase 1 clinical trial for the reversal of atherosclerotic plaque development and reduction of the risk of coronary events in patients with ACS; and Argatroban, which is a NDA filed direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis. The company sells its products through its sales representatives. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.
</blockquote>
Notes On Yahoo Finance Fundamentals:
MDCO has a forward P/E of 17, which is higher than its current P/E of under 7. As of January 13, MDCO has minimal shorts with only a ratio of 4.6.  One large benefit for MDCO is the significant cash of $307 million to no debt, providing much flexibility for the organization.  Lastly, the median price target for six analysts is $22.25 with a high target of $27.
Annotated Chart and Trade Details:
<a onclick="javascript:pageTracker._trackPageview('/downloads/wp-content/uploads/2012/01/MDCO-1-30.png');" href="http://michaelkudrna.com/wp-content/uploads/2012/01/MDCO-1-30.png"><img class="aligncenter size-medium wp-image-4527" title="MDCO 1-30" src="http://michaelkudrna.com/wp-content/uploads/2012/01/MDCO-1-30-300x165.png" alt="" width="300" height="165" /></a>
You can follow my trades alongside the <a onclick="javascript:pageTracker._trackPageview('/outgoing/seekingalpha.com/author/michael-kudrna/stocktalk');" href="http://seekingalpha.com/author/michael-kudrna/stocktalk" target="_blank">36,000 plus market players who follow me on SeekingAlpha</a> (Shameless promotion). As always, do your own homework to see if you agree. Good luck out there.
Mike
At the time of publication, Kudrna had no positions in mentioned stocks, but may initiate positions within 72 hours.
<a onclick="javascript:pageTracker._trackPageview('/outgoing/feeds.feedburner.com/~r/MichaelKudrna/~6/1');" href="http://feeds.feedburner.com/~r/MichaelKudrna/~6/1" target="_blank"><img class="c14" src="http://feeds.feedburner.com/MichaelKudrna.1.gif" alt="Kudrna's Stock Market Talk" /></a>
  
<h3>Similar Posts:</h3>
Tags: <a href="http://michaelkudrna.com/tag/charts/" rel="tag">Charts</a>, <a href="http://michaelkudrna.com/tag/dusa-pharma-dusa/" rel="tag">DUSA Pharma (<a class="ticker" href="/stock/dusa#">DUSA</a>)</a>, <a href="http://michaelkudrna.com/tag/fomc/" rel="tag">FOMC</a>, <a href="http://michaelkudrna.com/tag/fundamentals/" rel="tag">Fundamentals</a>, <a href="http://michaelkudrna.com/tag/greece/" rel="tag">Greece</a>, <a href="http://michaelkudrna.com/tag/iridium-communications-irdm/" rel="tag">Iridium Communications (<a class="ticker" href="/stock/irdm#">IRDM</a>)</a>, <a href="http://michaelkudrna.com/tag/michael-kudrna/" rel="tag">Michael Kudrna</a>, <a href="http://michaelkudrna.com/tag/potential-trades/" rel="tag">Potential Trades</a>, <a href="http://michaelkudrna.com/tag/stock-radar/" rel="tag">Stock Radar</a>, <a href="http://michaelkudrna.com/tag/the-medicines-company-mdco/" rel="tag">The Medicines Company (<a class="ticker" href="/stock/mdco#">MDCO</a>)</a>
This entry was posted on Monday, January 30th, 2012 at 11:38 PM and is filed under <a href="http://michaelkudrna.com/category/stock-market/" title="View all posts in Stock Market" rel="category tag">Stock Market</a>. You can follow any responses to this entry through the <a href="http://michaelkudrna.com/2012/01/potential-trades-this-week-looking-for-consolidation/feed/">RSS 2.0</a> feed. Responses are currently closed, but you can <a href="http://michaelkudrna.com/2012/01/potential-trades-this-week-looking-for-consolidation/trackback/" rel="trackback">trackback</a> from your own site.
</div>
<img src="http://pixel.quantserve.com/pixel/p-89EKCgBk8MZdE.gif" border="0" height="1" width="1" />

Topics

Personal Finance

IRDM

MDCO

Potential Trades This Week: Looking For Consolidation

Short Ideas

ASIA

AXAS

BLTI

EGHT

ENTR

FLML

FSIN

LOCM

ONTY

ZOLT

Weekly Traders Homework: Frustrated Bears

DUSA Pharmaceuticals (Nasdaq: <a class="ticker" href="/stock/dusa#Nasdaq">DUSA</a>) announced that it has been added to the U.S. broad-market Russell 3000® Index. Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 24, 2011.

DUSA Pharmaceuticals Added to Russell 3000 Index

Right now, about 58 million Americans suffer from 
 the most common form of skin pre-cancer - Actinic Kerotosis (AK). I say 
 pre-cancer because with the right treatment, this relatively common skin 
 condition can be prevented.
 

 But, if not treated properly there is a 
 possibility that the condition could get a lot worse - it could even 
 become life threatening.
 

 It is not my place to give you advice on which 
 medical treatments you should choose for particular illnesses and 
 conditions - I am not a doctor. However, I do specialize in finding 
 opportunities to invest in small cap growth companies that have the 
 opportunity to make significant returns.
 

 I have found a tiny $110 million market cap 
 biotech company that is helping to treat this condition, while providing 
 significant growth potential for investors.
 

 It specializes in skin-based 
 products.
 

 Its main product, Levulan Kerastick treats the 
 common precancerous skin condition Actinic Kerotosis (AK) which are 
 lesions caused by sun exposure. Last year over eight million people were 
 treated for AK, up 52.5 percent from 2005.
 

 The company is DUSA Pharmaceuticals 
 (Nasdaq: DUSA) and it is one the best growth stories I know of 
 in the small cap biotech space. The company turned in its first 
 profitable year during 2010 and has the potential to make generate 
 significant returns in 2011.
 

 Levulan is really the company's only product - it 
 alone accounted for $10.2 million of the $11 million in revenue the 
 company reported in the last quarter. Gross margins for the product also 
 reached a record high at 89 percent. But currently, the product only 
 makes up 5 percent of the market share for AK treatment, meaning there is 
 still tremendous market growth potential. And it is quickly eating away 
 at the competition due to the minimally invasive nature of the 
 product.
 

 Unlike its competitor's products, DUSA won't keep 
 its customers from going to the beach while being treated with Levulan. 
 Its competitors treat AK with topical creams, dermabrasion, chemical 
 peels, laser removal, or cryotherapy (freezing with liquid 
 nitrogen).
 

 Unfortunately, topical creams, dermabrasion and 
 chemical peels have a history of leaving scars or splotches while methods 
 such as freezing with liquid nitrogen are oftentimes not covered by 
 insurers. DUSA's product is far superior. It does not leave scars, is 
 covered by insurers and can be treated with one visit to the 
 dermatologist.
 

  
 

 Dermatologists are taking notice. Investors are 
 sure to follow. And sales are rapidly increasing.
 

 With revenues surging by 25.6 percent in 2010, 
 Levulan is clearly generating a loyal following. Gross margins have 
 steadily increased over the past five years with the latest gross margin 
 hitting 80 percent in 2010. Gross margin is expected to increase above 81 
 percent in 2011. And with DUSA's leading product eating away at market 
 share I would expect to see the 25 percent growth rate continue for a few 
 more years.
 

 Like most small cap biotech companies DUSA is 
 highly dependent on one product - a potential weakness. However, its 
 rapid growth rate should lead to significant gains through share price 
 appreciation.
 

 As I write this, the stock is up approximately 25 
 percent. DUSA reported revenue growth of 27 percent in the first quarter 
 of 2011, compared with the same quarter last year. It did experience a 
 net loss on a GAAP basis of 0.02 per share for the first quarter. The 
 loss can be attributed to the fair value accounting of the warrants that 
 were issued in 2007. This adjustment does not concern me so much since it 
 is a paper transaction only, and it obviously does not concern the market 
 with the share price advancing 25 percent after the earnings report was 
 released.
 

 With an annual sales growth rate of approximately 
 25 percent and a forward P/E of 22.8 I would be a buyer up to the $6.50 
 to $6.75 level. The stock currently trades for $5.71 so you have around 
 13.8 percent upside from here before the stock looks too stretched to 
 start a position. If the current growth trend continues, as I believe it 
 will, I could easily see the share price reach $8.50 to $10 by the end of 
 the year.

Preventing the Most Common Form of Cancer (DUSA)

Best

1) Kendle International (NASDAQ: <a class="ticker" href="/stock/kndl#NASDAQ">KNDL</a>): Trading up 58% from yesterday's close to $15.01. Kendle International is to be acquired by INC Research for $15.25 per share in cash. The deal is valued at $232 million.
										


2) DUSA Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/dusa#NASDAQ">DUSA</a>): Trading up 26.5% from yesterday's close to $5.73. DUSA reported a loss of $0.02 per share versus a $0.02 loss per share for the same period last year.

3) Gibralter Industries (NASDAQ: <a class="ticker" href="/stock/rock#NASDAQ">ROCK</a>): Trading up 21.3% from yesterday's close to $13.25. Gibralter reported earnings of $0.05 per share versus a loss of $0.08 per share for the same period last year. Net income rose to $8.4 million compared to a loss of $21.2 million for the same quarter last year.

4) Polypore International (NYSE: <a class="ticker" href="/stock/ppo#NYSE">PPO</a>): Trading up 20.2% from yesterday's close to $66.60. Polypore reported earnings of $0.55 cents per share versus estimates of $0.39 per share. Revenue came in at $27.5 million.		

5) Blue Dolphin Energy (NASDAQ: <a class="ticker" href="/stock/bdco#NASDAQ">BDCO</a>): Trading up 18.6% from yesterday's close to $6.45. 

Other Notable Gainers

Men's Wearhouse (NYSE: <a class="ticker" href="/stock/mw#NYSE">MW</a>): Trading up 15.6% from yesterday's close to $32.29. Men's Wearhouse raised its first-quarter guidance to $0.47 - $0.50 per share versus estimates of $0.29 per share.

Fonar (NASDAQ: <a class="ticker" href="/stock/fonr#NASDAQ">FONR</a>): Trading up 13.8% from yesterday's close to $2.14.		

Leap Wireless International (NASDAQ: <a class="ticker" href="/stock/leap#NASDAQ">LEAP</a>): Trading up 13.4% from yesterday's close to $17.09. Leap Wireless was upgraded from Neutral to Buy by Collins Stewart.

Worst

1) Timberland (NYSE: <a class="ticker" href="/stock/tbl#NYSE">TBL</a>): Trading down 26.8% from yesterday's close to $30.41. Timberland reported earnings of $0.35 cents per share versus estimates of $0.59 per share. Revenue came in at $349 million versus estimates of $361 million.

2) Sino Clean Energy (NASDAQ: <a class="ticker" href="/stock/scei#NASDAQ">SCEI</a>): Trading down 24.3% from yesterday's close to $2.64. Sino Clean announced that it intends to take action against parties responsible for “malicious and fraudulent attacks” on the company, which, the company claims, was by or on behalf of short sellers.

3) Smith Micro Software (NASDAQ: <a class="ticker" href="/stock/smsi#NASDAQ">SMSI</a>): Trading down 22.2% from yesterday's close to $5.65. Smith Micro forecast revenue for the second quarter of $15 to 20 million versus estimates of $24.2 million. The company was downgraded from Buy to Hold at Canaccord.

4) Savient Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/svnt#NASDAQ">SVNT</a>): Trading down 17.7% from yesterday's close to $9.13. Savient reported earnings of -$0.19 per share versus estimates of -$0.31 per share. Revenue came in at $1.3 million versus estimates of $2 million.	

5) Global Industries (NASDAQ: <a class="ticker" href="/stock/glbl#NASDAQ">GLBL</a>): Trading down 16.6% from yesterday's close to $7.31. Global Industries reported earnings of -$0.30 per share versus -$0.19 per share for the same period last year. The company posted a net loss of $33.9 million compared to a net loss of $21.4 million for same quarter last year.			

Other Notable Losers

Union Drilling (NASDAQ: <a class="ticker" href="/stock/udrl#NASDAQ">UDRL</a>): Trading down 14.5% from yesterday's close to $10.01. Union drilling reported a loss of $0.20 per share on $56 million in revenue for the first quarter.

Aeropostale (NYSE: <a class="ticker" href="/stock/aro#NYSE">ARO</a>): Trading down 15.5% from yesterday's close to $21.53. Aeropostale cut its second quarter guidance to $0.20 per share versus its forecast of $0.35 to $0.38 per share.

Deer Consumer Products (NASDAQ: <a class="ticker" href="/stock/deer#NASDAQ">DEER</a>): Trading down 13.5% from yesterday's close to $8.60. Deer received harsh criticism from Jim Cramer yesterday. The host said, “Do not buy shares of this Chinese appliance company,” citing it as “an accounting morass.”

Jim Cramer

Small Cap Analysis

Movers & Shakers

Intraday Update

BDCO

DEER

FONR

GLBL

KNDL

LEAP

ROCK

SCEI

SMSI

SVNT

UDRL

Top Percentage Gainers and Losers as of 2pm 04/05/11 (KNDL, DUSA, ROCK, PPO, BDCO, MW, FONR, LEAP, TBL, SCEI, SMSI, SVNT, GLBL, DEER, UDRL, ARO)

Best

1) Kendle International (NASDAQ: KNDL): Trading up 57.8% from yesterday's close to $14.99. Kendle International is to be acquired by INC Research for $15.25 per share in cash. The deal is valued at $232 million.
										


2) Polypore International (NYSE: PPO): Trading up 20.8% from yesterday's close to $66.49. Polypore reported earnings of $0.55 cents per share versus estimates of $0.39 per share. Revenue came in at $27.5 million.

3) DUSA Pharmaceuticals (NASDAQ: DUSA): Trading up 20% from yesterday's close to $5.44. DUSA reported a loss of -$0.02 per share versus -$0.02 for the same period last year.

4) Gibralter Industries (NASDAQ: ROCK): Trading up 19% from yesterday's close to $13.02. Gibralter reported earnings of $0.05 per share versus a loss of $0.08 per share for the same period last year. Net income rose to $8.4 million compared to a loss of $21.2 million for the same quarter last year.

5) Sauer-Danfoss (NYSE: SHS): Trading up 17.2% from yesterday's close to $64.50. Sauer-Danfoss reported earnings of $1.46 per share versus $0.43 per share for the same period last year. Revenue increased 46% to $565.7 million.

Worst

1) Timberland (NYSE: TBL): Trading down 29% from yesterday's close to $29.50. Timberland reported earnings of $0.35 cents per share versus estimates of $0.59 per share. Revenue came in at $349 million versus estimates of $361 million.

2) Smith Micro Software (NASDAQ: SMSI): Trading down 22.5% from yesterday's close to $5.63. Smith Micro forecast revenue for the second quarter of $15 to 20 million versus estimates of $24.2 million. The company was downgraded from Buy to Hold at Canaccord.

3) Aeropostale (NYSE: ARO): Trading down 15.5% from yesterday's close to $21.53. Aeropostale cut its second quarter guidance to $0.20 per share versus its forecast of $0.35 to $0.38 per share.


4) Sino Clean Energy (NASDAQ: SCEI): Trading down 15.4% from yesterday's close to $2.96. Sino Clean announced that it intends to take action against parties responsible for “malicious and fraudulent attacks” on the company, which, the company claims, was by or on behalf of short sellers.

5) Savient Pharmaceuticals (NASDAQ: SVNT): Trading down 14.2% from yesterday's close to $9.51. Savient reported earnings of -$0.19 per share versus estimates of -$0.31 per share. Revenue came in at $1.3 million versus estimates of $2 million.

Top Percentage Gainers and Losers as of 12pm 04/05/11 (KNDL, PPO, DUSA, ROCK, SHS, TBL, SMSI, ARO, SCEI, SVNT)

Comments

Davis Fundamental ETF Trust Davis Select U.S. Equity ETF

Actualités

Dernières nouvelles pour Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS:DUSA)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL